Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage
NCT07614906
Aneurysmal Subarachnoid Hemorrhage, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT Number: NCT05851989
The SPARTA study is a prospective multicenter observational trial in the Netherlands with the aim of identifying the best clinical care in patients with aneurysmal subarachnoidal haemorrhage. Differences in outcome between surgical treatment and endovascular treatment will be explored.
Furthermore, cost effectiveness and radiological prognostic factors will be examined.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Amsterdam UMC, Amsterdam, Netherlands
Rationale:
Ruptured intracranial aneurysms resulting in subarachnoid haemorrhage can be treated by open surgical treatment or endovascular treatment. Despite multiple previous studies, biases and uncertainty around the best current treatment practice still exist. The resulting variation of care may result in a variable outcome. The protocol for a prospective multicentre observational study aimed at comparing the effectiveness of different treatment strategies in patients with ruptured aneurysms is presented.
Objective:
The primary aim of this study is to identify the effectiveness of clipping versus coiling on functional outcome in patients presenting with a subarachnoid haemorrhage due to a ruptured intracranial aneurysm 1 year after onset of symptoms. Secondary objectives include long term functional outcome, complications, cost-effectiveness and explorative analysis of the diagnostic and prognostic value of radiological imaging.
Study design:
This multi-centre study will have an observational prospective cohort design. Patient will have a follow-up of maximum 10 years.
Study population:
Patients with a subarachnoid haemorrhage will be included. Patients with evident other causes and patients without diagnosis of intracranial aneurysm after six months will be excluded.
Main study parameters/endpoints:
The primary endpoint is the score on the modified Rankin scale (mRs) and mortality at 1 year after the initial SAH. Secondary endpoints include the mRs, Modified Telephone Interview of Cognitive Status (TICS-M), 5-level EuroQol-5D (EQ-5D-5L) and derived Quality of Life Years, costs from patient diaries, and the Hospital Anxiety and Depression Scale (HADS), measured at 6 months, 1, 2, 5 and 10 years.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Patients will receive 'nonexperimental' regular care during their hospital stay. For this study, health questionnaires and functional outcome will be assessed at baseline, follow-up visits and before discharge. Temporary fatigue is the only possible side-effect of completion of the questionnaires.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year after onset of symptoms
Scoring of functional outcome using the modified Rankin Scale. The scale has a minimum value of 0, meaning no symptoms, and a maximum value of 6, meaning dead. The modified Rankin Scale measures the degree of dependence. A higher score means a worse outcome.
Time frame: 6 months, 1, 2, 5 and 10 years after onset of symptoms
Scoring of functional outcome using the modified Rankin Scale. The scale has a minimum value of 0, meaning no symptoms, and a maximum value of 6, meaning dead. The modified Rankin Scale measures the degree of dependence. A higher score means a worse outcome.
Time frame: 6 months, 1, 2, 5 and 10 years after onset of symptoms
Scoring of cognitive outcome using the Modified Telephone Interview for Cognitive Status. This type of scoring contains multiple elements for detecting anamnestic mild cognitive impairment. The score ranges from 0 to 50, a higher score means a better outcome.
Time frame: 6 months, 1, 2, 5 and 10 years after onset of symptoms
Scoring of quality of life using the 5-level EuroQol-5D questionnaire. The questionnaire contains 5 scores in 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. A higher score means a worse outcome.
Time frame: 3 months, 6 months, 1, 2, 5 and 10 years after onset of symptoms
Estimation of societal costs by completion of a custom healthcare consumption and loss of productivity (paid and unpaid) questionnaire at 3 months, 6 months, 1 year, 2 years, 5 years and 10 years.
Time frame: 6 months, 1, 2, 5 and 10 years after onset of symptoms
Degree of occlusion in % of the aneurysm measured on imaging during follow-up using Computed Tomography, Diagnostic Angiography or Magnetic Resonance Imaging. A higher degree of occlusion means a better outcome.
Contact information is provided by the study sponsor or research team.
Rick Vreeburg, MD
CONTACT
Wouter Moojen, MD, PhD
CONTACT
Haaglanden Medical Centre
Other
Acronym: SPARTA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07614906
Aneurysmal Subarachnoid Hemorrhage, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07250958
Aneurysmal Subarachnoid Hemorrhage, Brain Diseases
Louisville, Kentucky, United States
View Trial DetailsNCT06284642
Aneurysmal Subarachnoid Hemorrhage, Brain Diseases
Hefei, Anhui, China
View Trial DetailsNCT05738083
Aneurysmal Subarachnoid Hemorrhage, Brain Diseases
Nanchang, Jiangxi, China
View Trial Details